Table 3.

Comparison of clinical characteristics of ELR and LLR patients in the locoregional recurrence group.

Characteristic	Total	ELR group	LLR group	P-value
	(n = 182)%	(n = 87)%	(n = 95)%
Age (years)				0.088
≤46 years	101 (55.5)	54 (62.1)	47 (49.5)
>46 years	81 (44.5)	33 (37.9)	48 (50.5)
Gender				0.162
Male	138 (75.8)	70 (80.5)	68 (71.6)
Female	44 (24.2)	17 (19.5)	27 (28.4)
Smoking status				0.870
Non-smoker	112 (61.5)	53 (60.9)	59 (62.1)
Smoker	70 (38.5)	34 (39.1)	36 (37.9)
Alcohol abuse				0.569
Non-drinker	154 (84.6)	75 (86.2)	79 (83.2)
Drinker	28 (15.4)	12 (13.8)	16 (16.8)
Tumor family history				0.603
No	137 (75.3)	67 (77.0)	70 (73.7)
Yes	45 (24.7)	20 (23.0)	25 (26.3)
Cranial nerve symptom				0.427
N0	172 (94.5)	81 (93.1)	91 (95.8)
Yes	10 (5.5)	6 (6.9)	4 (4.2)
Baseline value of EBV-DNA				0.728
≤2,000	63 (34.6)	29 (33.3)	34 (35.8)
>2,000	119 (65.4)	58 (66.7)	61 (64.2)
Histological type				0.246
WHO I/II	10 (5.5)	3 (3.4)	7 (7.4)
WHO III	172 (94.5)	84 (96.6)	88 (92.6)
T stage				0.552
1/2	39 (21.4)	17 (19.5)	22 (23.2)
3/4	143 (78.6)	70 (80.5)	73 (76.8)
N stage				0.316
0/1	97 (53.3)	43 (49.4)	54 (56.8)
2/3	85 (46.7)	44 (50.6)	41 (43.2)
TNM stage				0.826
I/II	22 (12.1)	11 (12.6)	11 (11.6)
III/IV	160 (87.9)	76 (87.4)	84 (88.4)
Induction chemotherapy				0.399
No	77 (42.3)	34 (39.1)	43 (45.3)
Yes	105 (57.7)	53 (60.9)	52 (54.7)
Concurrent chemotherapy				0.203
No	29 (15.9)	17 (19.5)	12 (12.6)
Yes	153 (84.1)	70 (80.5)	83 (87.4)
Adjuvant chemotherapy				0.065
No	173 (95.1)	80 (92.0)	93 (97.9)
Yes	9 (4.9)	7 (8.0)	2 (2.1)
Post-recurrence treatment options				0.415
BST	9 (4.9)	5 (5.7)	4 (4.2)
Salvage surgery	43 (23.6)	22 (25.3)	21 (22.1)
Re-irradiation	70 (38.5)	28 (32.2)	42 (44.2)
Chemotherapy	60 (33.0)	32 (36.8)	28 (29.5)